Eikon Therapeutics offers large modeled analyst upside typical of a speculative biotech, but weak quality metrics, margin compression, leverage, and consecutive earnings misses keep the risk profile elevated.
Thesis pillars
- Value Trap Margin Leverage→Stable
- Quality Below Floor No Moat→Stable
- Overbought Bear Rally Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Eikon Therapeutics, Inc. (EIKN) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.72: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality.
Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking (SMT) technology platform to discover and develop cancer therapeutics, led by drug developers Dr. Roger Perlmutter and Dr. Roy Baynes. The company's most advanced... Read more
Sell if holding. Engine safety override at $10.72: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 36d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyin-licensed product candidates10-K Item 1A: 'EIK1005 is the only product candidate in clinical development that has leveraged our technology platform. Rights related to all other clinical-stage products candidates are in-licensed.'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02LOWEikon Therapeutics appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director effective June 15, 2026, to serve on the Compensation Committee; she will receive standard non-employee director compensation including a $50,000 annual retainer and an option to purchase 85,937 shares at $8.96 per share.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.72: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.97. Score 5.3/10, moderate confidence.
Take-profit target: $21.58 (+101.3% upside). Prior stop was $9.97. Stop-loss: $9.97.
Concentration risk — Counterparty: in-licensed product candidates; Quality below floor (2.4 < 4.0).
Eikon Therapeutics, Inc. trades at a P/E of N/A (forward -1.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover EIKN with a consensus score of 3.9/5. Average price target: $25.
What does Eikon Therapeutics, Inc. do?Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking...
Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking (SMT) technology platform to discover and develop cancer therapeutics, led by drug developers Dr. Roger Perlmutter and Dr. Roy Baynes. The company's most advanced candidate, EIK1001, a TLR 7/8 dual-agonist in-licensed from Seven and Eight Biotherapeutics, is in a global Phase 2/3 registrational trial combined with pembrolizumab for advanced melanoma, alongside PARP1 inhibitors EIK1003 and EIK1004 and internally discovered candidate EIK1005.